The Lemon Fool

GlaxoSmithKline plc (LSE/NYSE: GSK) today announces that Sir Philip Hampton has informed the Board of his intention to step down as non-executive Chairman and the Board has started the process to find a successor.

In reference to the announcement issued by the Serious Fraud Office ("SFO") today, GlaxoSmithKline plc (LSE/NYSE: GSK) is pleased that the SFO have closed their investigation and concluded that no further action is required.

ViiV Healthcare presents positive, 48-week data from two pivotal phase III studies showing long-acting, injectable two-drug regimen of cabotegravir and rilpivirine has similar efficacy to daily, three-drug oral treatment in adults living with HIV-1 infection

FTSE 100 pharma giant GlaxoSmithKline (LSE: GSK) is heading for a break-up. Chief executive Emma Walmsley will oversee the creation of two companies — a focused and faster-growing pharmaceutical company and a profitable, stable consumer healthcare business.

This strategy isn’t a sure thing, but I think there’s a good chance it will work. Today I’ll explain why. I’ll also take a look a FTSE 250 stock which I think offers an interesting mix of opportunity and risk.

A break-up makes sense

maximan wrote:
Sorry link keeps failing. It is on Investigate if you go direct.

ViiV Healthcare today announced that the US Food and Drug Administration (FDA) approved Dovato, a complete, once-daily, single-tablet regimen of dolutegravir (DTG) 50 mg and lamivudine (3TC) 300 mg for the treatment of HIV-1 infection in adults with no antiretroviral (ARV) treatment history and with no known resistance to either DTG or 3TC. Dovato, a two-drug regimen (2DR), reduces exposure to the number of ARVs from the start of treatment, while still maintaining the efficacy and high barrier to resistance of a traditional DTG-based three-drug regimen.1

GlaxoSmithKline (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved two new methods for administering Nucala (mepolizumab), an autoinjector and a pre-filled safety syringe, for patients or caregivers to administer once every four weeks, after a healthcare professional decides it is appropriate. This is the first anti-IL5 biologic to be licensed in the US for at-home administration, and the first respiratory biologic to be approved for administration via an autoinjector.

ViiV Healthcare announces phase III study meets primary endpoint, demonstrating the ability to control HIV-1 with a 2-drug regimen of dolutegravir plus lamivudine in virally suppressed patients switching from a TAF-containing, 3-drug regimen

idpickering wrote:ViiV switch study shows 2DR as effective as 3DR

ViiV Healthcare announces phase III study meets primary endpoint, demonstrating the ability to control HIV-1 with a 2-drug regimen of dolutegravir plus lamivudine in virally suppressed patients switching from a TAF-containing, 3-drug regimen

https://www.investegate.co.uk/glaxosmit ... 00030093F/

tjh290633 wrote:My broker has sent me a notice of Corporate Action today, regarding the splitting off of the new Joint Venture with Pfizer.

Other than the vote having been passed at the AGM approving this, I have seen nothing else. No RNS of recent date. I have had a look on the GSK website and see nothing there. Have I missed something, or is this in anticipation of an announcement with the Q1 results next week?

TJH

Demerger.

Share holders will recieve Consumer Healthcare Joint Venture (CHJV) shares, at a rate to be determined for each Existing GlaxoSmithKline PLC (GSK) share held on the Ex-entitlement Date, which is yet to be determined.
Important Information & Other Key Dates:
On 19th December 2018, GSK and Pfizer entered into an agreement under which, upon closing of the proposed transaction, Pfizer will contribute its consumer healthcare business to GSK's existing consumer healthcare business in return for equity shares in this business. As a result, a newly Demerged Consumer Health Joint Venture will be created in which GSK will have a controlling 68 percent equity interest and Pfizer 32 percent equity interest.

The Demerger received shareholder approval at the General Meeting held on 8th May 2019.